This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Has National Vision (EYE) Outpaced Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Here is how National Vision (EYE) and Pilgrim's Pride (PPC) have performed compared to their sector so far this year.
How Much Upside is Left in National Vision (EYE)? Wall Street Analysts Think 28.92%
by Zacks Equity Research
The mean of analysts' price targets for National Vision (EYE) points to a 28.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
EYE vs. CL: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. CL: Which Stock Is the Better Value Option?
National Vision (EYE) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why National Vision (EYE) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EYE Q4 Loss Narrower Than Expected, Margins Rise, Stock Surges
by Zacks Equity Research
Continued strength in Managed Care aids National Vision's fourth-quarter 2024 performance.
National Vision (EYE) Reports Q4 Loss
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 20% and 0%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Is it the Right Time to Hold EYE Stock in Your Portfolio Now?
by Zacks Equity Research
National Vision continues to draw investors' attention with its strategic transformation efforts, while positive industry trends should favor its growth.
Leslie's, Inc. (LESL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Leslies (LESL) delivered earnings and revenue surprises of -4.76% and 1.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights General Motors, Dana, Valero, National Vision and Avis Budget
by Zacks Equity Research
General Motors, Dana, Valero, National Vision and Avis Budget have been highlighted in this Screen of The Week article.
Clorox (CLX) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Clorox (CLX) delivered earnings and revenue surprises of 11.51% and 3.12%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
5 Broker-Favorite Stocks to Keep an Eye on Amid Current Volatility
by Maharathi Basu
Investors should keep a tab on stocks like General Motors, Dana, Valero Energy, National Vision and Avis Budget for high returns.
Why National Vision (EYE) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
National Vision (EYE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Despite Fast-paced Momentum, National Vision (EYE) Is Still a Bargain Stock
by Zacks Equity Research
National Vision (EYE) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
EYE or CLX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. CLX: Which Stock Is the Better Value Option?
5 Broker-Loved Stocks to Monitor Amid Signs of Slowing Inflation
by Maharathi Basu
Investors should keep a tab on stocks like National Vision, Cencora, ABM, Arrow Electronics and Bunge Global for high returns.
Should National Vision Stock Be in Your Portfolio Right Now?
by Zacks Equity Research
Investors are optimistic about EYE stock, courtesy of its share gain in the Owned and Host segments.
National Vision (EYE) Down 4.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Reasons to Retain EYE Stock in Your Portfolio for Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.
National Vision Q3 Earnings Top Estimates, Revenues Lag, Stock Tumbles
by Zacks Equity Research
EYE's third-quarter 2024 results reflect ongoing strength in Managed Care, with growth in America's Best stores.
National Vision (EYE) Q3 Earnings Surpass Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 140% and 0.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: National Vision (EYE) Q3 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exclusive Partnership With Pair Eyewear Likely to Support EYE Stock
by Zacks Equity Research
National Vision's America's Best stores become the exclusive retail partner of Pair Eyewear.
Reasons to Retain EYE Stock in Your Portfolio for Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust market expansion of the Owned and Host segment bode well for National Vision.